The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 8, 2023. Its latest SEC filing is a 15-12G from Aug 21, 2023.
10-Q for Q2 FY2023, filed Aug 8, 2023
The sections below describe the company as of the FY2022 annual report.
Develops oral drug candidates for chronic immune diseases such as psoriasis and inflammatory bowel disease, aiming to offer an alternative to injected medicines.
10-K for FY2022, filed Mar 15, 2023We are a biopharmaceutical company leveraging our proprietary technology platform to build a pipeline of novel oral therapeutic candidates…View ↗
Our lead therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (“IL-17”), which…View ↗
We also are developing oral therapeutic candidates targeting α4ß7 integrin for the treatment of inflammatory bowel disease (“IBD”) and…View ↗
Alpha 4 beta 7 (“α4ß7”) is a powerful signaling molecule embedded in the cell membranes of immune cells and is an established target for…View ↗
Sanofi and Genentech worked with DICE under research collaborations; Sanofi also held an exclusive option to license compounds.
10-K for FY2022, filed Mar 15, 2023
10-Q for Q2 FY2023, filed Aug 8, 2023
−$34.8MView ↗
8-K, filed Aug 9, 2023
As a result of the consummation of the Offer and the consummation of the Merger in accordance with Section 251(h) of the DGCL on August 9…View ↗
8-K, filed Jun 20, 2023
On June 18, 2023, Eli Lilly and Company, an Indiana corporation (“Parent”), Durning Acquisition Corporation, a Delaware corporation and a…View ↗
Competes with Novartis, Eli Lilly, Bausch Health, UCB, Abbvie, Sun Pharmaceutical Industries, Janssen Pharmaceuticals, Amgen, Bristol Myers Squibb, Takeda Pharmaceutical, Ventyx Biosciences, LEO Pharma, Biogen, Arena Pharmaceuticals, Morphic Therapeutic, Boehringer Ingelheim, and Roche
10-K for FY2022, filed Mar 15, 2023We are advancing our lead program, DC-806, an antagonist of IL-17 being developed initially for the treatment of psoriasis, with the…View ↗
Loading...
